Overview

A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765

Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study will provide data to support preclinical to clinical translation by aligning preclinical and clinical efficacy assay with dose dependent changes in EEG.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Ketamine